Credit Suisse’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-889,268
| Closed | -$16M | – | 4231 |
|
|
2020
Q2 | $16M | Buy |
889,268
+778,481
| +703% | +$10.8M | 0.01% | 1061 |
|
|
2020
Q1 | $790K | Sell |
110,787
-186,057
| -63% | -$2.32M | ﹤0.01% | 2834 |
|
|
2019
Q4 | $7.09M | Buy |
296,844
+161,580
| +119% | +$4.46M | 0.01% | 1634 |
|
|
2019
Q3 | $3.63M | Buy |
135,264
+73,515
| +119% | +$2.06M | ﹤0.01% | 2013 |
|
|
2019
Q2 | $1.68M | Sell |
61,749
-214
| -0.3% | -$6.71K | ﹤0.01% | 2581 |
|
|
2019
Q1 | $2.15M | Buy |
61,963
+6,853
| +12% | +$198K | ﹤0.01% | 2319 |
|
|
2018
Q4 | $1.08M | Sell |
55,110
-317,902
| -85% | -$6.54M | ﹤0.01% | 2719 |
|
|
2018
Q3 | $9.93M | Sell |
373,012
-17,903
| -5% | -$585K | 0.01% | 1262 |
|
|
2018
Q2 | $14.8M | Sell |
390,915
-213,408
| -35% | -$8.16M | 0.01% | 1011 |
|
|
2018
Q1 | $19.7M | Buy |
604,323
+366,464
| +154% | +$16.1M | 0.02% | 860 |
|
|
2017
Q4 | $11.6M | Buy |
237,859
+96,490
| +68% | +$4.88M | 0.01% | 1175 |
|
|
2017
Q3 | $7.64M | Buy |
141,369
+33,424
| +31% | +$1.96M | 0.01% | 1423 |
|
|
2017
Q2 | $6.06M | Sell |
107,945
-46,466
| -30% | -$1.86M | 0.01% | 1512 |
|
|
2017
Q1 | $6.05M | Buy |
154,411
+49,068
| +47% | +$1.56M | 0.01% | 1521 |
|
|
2016
Q4 | $2.36M | Buy |
105,343
+38,937
| +59% | +$761K | ﹤0.01% | 2312 |
|
|
2016
Q3 | $1.51M | Buy |
66,406
+3,884
| +6% | +$91.2K | ﹤0.01% | 2601 |
|
|
2016
Q2 | $1.48M | Sell |
62,522
-28,069
| -31% | -$693K | ﹤0.01% | 2588 |
|
|
2016
Q1 | $1.85M | Buy |
90,591
+34,132
| +60% | +$1.08M | ﹤0.01% | 2269 |
|
|
2015
Q4 | $2.9M | Buy |
56,459
+2,668
| +5% | +$129K | ﹤0.01% | 2016 |
|
|
2015
Q3 | $2.29M | Sell |
53,791
-31,286
| -37% | -$1.51M | ﹤0.01% | 2156 |
|
|
2015
Q2 | $3.88M | Buy |
85,077
+19,498
| +30% | +$784K | ﹤0.01% | 1958 |
|
|
2015
Q1 | $2.49M | Buy |
65,579
+26,696
| +69% | +$917K | ﹤0.01% | 2213 |
|
|
2014
Q4 | $1.1M | Buy |
38,883
+20,081
| +107% | +$558K | ﹤0.01% | 3046 |
|
|
2014
Q3 | $476K | Sell |
18,802
-24,443
| -57% | -$644K | ﹤0.01% | 3678 |
|
|
2014
Q2 | $1.26M | Buy |
43,245
+26,833
| +163% | +$649K | ﹤0.01% | 3086 |
|
|
2014
Q1 | $425K | Buy |
16,412
+2,157
| +15% | +$57.6K | ﹤0.01% | 3832 |
|
|
2013
Q4 | $367K | Buy |
14,255
+5,923
| +71% | +$144K | ﹤0.01% | 3944 |
|
|
2013
Q3 | $222K | Buy |
+8,332
| New | +$198K | ﹤0.01% | 3921 |
|
Credit Suisse's PTLA Position: Q3 2020 in Review
Credit Suisse sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 889,268 shares — an estimated $16M sold.
Credit Suisse first reported a position in PTLA in Q3 2013 and held it in 28 quarters. The position peaked at $19.7M in Q1 2018. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Credit Suisse reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Credit Suisse sold 889,268 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $16M.
- Credit Suisse first reported a position in Portola Pharmaceuticals, Inc. in Q3 2013 and held it in 28 quarters.
- Credit Suisse's Portola Pharmaceuticals, Inc. position peaked at $19.7M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Credit Suisse's 13F filing for Q3 2020, filed 13 Nov 2020.